Physician global assessments or blood tests do not predict mucosal disease activity in ulcerative colitis

Canadian Journal of Gastroenterology and Hepatology

Volumn 28, Issue 6, 2014, Pages 325-329

  Brahmania, Mayur ^a   Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Mucosal healing; Physician global assessment; Ulcerative colitis; Ulcerative colitis endoscopic index of severity (uceis)

Indexed keywords

ADALIMUMAB; ALBUMIN; AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; FERRITIN; INFLIXIMAB; MERCAPTOPURINE;

ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL ASSESSMENT; COLON MUCOSA; COLONOSCOPY; FEMALE; HUMAN; INTESTINE ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; ULCERATIVE COLITIS; BLOOD; EVALUATION STUDY; INTESTINE MUCOSA; MANITOBA; PATHOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MANITOBA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84902673914     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2014/737349     Document Type: Article

References (23)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25.
2. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008;2:1-23. (Pubitemid 351179487)
3. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982;12:351-9. (Pubitemid 12024511)
4. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroeterology 2011;140:1817-26.
5. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-5. (Pubitemid 46580492)
6. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83.
7. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22. (Pubitemid 47187355)
8. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483-9.
9. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis? A prospective study. Am J Gastroenterol 2010;105:1150-7.
10. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
11. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42.
12. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
13. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: Indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005;3:11-24. (Pubitemid 40092938)
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br Med J 1955;2:1041-8.
15. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89-92.
16. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7. (Pubitemid 9067125)
17. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8. (Pubitemid 17072238)
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
19. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. Br Med J 1989;298:82-6. (Pubitemid 19032930)
20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507. (Pubitemid 41007865)
21. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87:971-6.
22. Shine B, Berghouse L, Jones JE. et al C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985;148:105-9. (Pubitemid 15034646)
23. Vermeire S, Van Assche G, Rutgeers P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006;55:426-43.